Pulmotect Revenue and Competitors
Estimated Revenue & Valuation
- Pulmotect's estimated annual revenue is currently $1.7M per year.
- Pulmotect's estimated revenue per employee is $155,000
Employee Data
- Pulmotect has 11 Employees.
- Pulmotect grew their employee count by 10% last year.
Pulmotect's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and Chief Operating Officer | Reveal Email/Phone |
2 | Medical Director | Reveal Email/Phone |
3 | Project Manager | Reveal Email/Phone |
4 | President | Reveal Email/Phone |
5 | Head, Clinical Operations and Consultant | Reveal Email/Phone |
Pulmotect Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.5M | 16 | 45% | N/A | N/A |
#2 | $13.8M | 89 | -7% | N/A | N/A |
#3 | $18.6M | 120 | 3% | $1.8M | N/A |
#4 | $0.9M | 6 | -40% | N/A | N/A |
#5 | $4.2M | 27 | 0% | N/A | N/A |
#6 | $3.4M | 22 | 47% | N/A | N/A |
#7 | $9.6M | 62 | 29% | N/A | N/A |
#8 | $0.9M | 6 | 20% | N/A | N/A |
#9 | $1.7M | 11 | 10% | N/A | N/A |
#10 | $15.2M | 98 | -8% | N/A | N/A |
What Is Pulmotect?
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body's innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens. Pulmotect’s initial market focus is on the reduction of chronic obstructive pulmonary disease (COPD) exacerbations, which are characterized by an acute worsening of symptoms mostly precipitated by a bacterial or viral infection.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 11 | 0% | $3M |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $1M | 11 | N/A | N/A |
#5 | $1.3M | 11 | N/A | N/A |